AstraZeneca stomach cancer drug doubles survival in late-stage trial (AZN:NYSE)
· seekingalpha.com
AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial, boosting oncology sales hopes.
AstraZeneca (AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, strengthening prospects for a medicine th...